Integra LifeSciences vs Penumbra
IART and PEN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IART and PEN compare
Penumbra is the larger company, worth 13 times as much as Integra LifeSciences ($12.6B against $992M).
Penumbra grew revenue faster over the last twelve months (17.0% versus 1.6% for Integra LifeSciences).
Penumbra keeps more of each dollar of sales as profit, with a net margin of 10.1% compared with −0.44% at Integra LifeSciences.
Penumbra scores higher on the StockData Score (15 against 9 for Integra LifeSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IART | PEN |
|---|---|---|
| Size and price | ||
| Market cap | $992M | $12.6B |
| Share price | $12.75 | $318.95 |
| Change, 1 year | −17.4% | 36.7% |
| Change, 5 years | −82.3% | 11.8% |
| Beta (5Y) | 1.28 | 0.87 |
| Employees | 3,700 | 4,700 |
| StockData Score | ||
| Total score | 9 | 15 (better) |
| Valuation score | 4 (better) | 2 |
| Growth score | 1 | 3 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 80.3× |
| P/S | 0.6× (better) | 8.1× |
| P/B | 1.0× (better) | 7.9× |
| EV/EBITDA | 10.9× (better) | 56.8× |
| P/FCF | 38.4× (better) | 62.7× |
| FCF yield | 2.6% (better) | 1.6% |
| Fair value | $21.82 | $184.29 |
| Margin of safety | 41.6% (better) | −73.1% |
| Growth | ||
| Revenue growth (TTM) | 1.6% | 17.0% (better) |
| Revenue growth, 5Y average | 3.6% | 20.2% (better) |
| Net income growth (TTM) | – | −4.3% |
| EPS growth (TTM) | – | −4.1% |
| Profitability | ||
| Gross margin | 52.5% | 68.0% (better) |
| Operating margin | 4.0% | 12.1% (better) |
| Net margin | −0.44% | 10.1% (better) |
| FCF margin | 1.6% | 12.8% (better) |
| Return on equity | −0.70% | 10.7% (better) |
| Return on invested capital | 6.7% | 15.9% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | 0.7× | 149× (better) |
| Current ratio | 3.60 | 5.89 (better) |
| Altman Z-score | 1.22 | 19.07 (better) |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 94.4% | 86.7% |
| Held by insiders | 3.4% | 3.4% |
| Insider net buying, 12 months | $102K (better) | −$11.1M |
| Short interest, % of float | 9.7% | 5.9% |
Go deeper
- IART stock overview
- IART income statement
- IART valuation and score
- PEN stock overview
- PEN income statement
- PEN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.